|
Jul 28
|
Could bispecifics unseat Keytruda from its oncology throne?
|
|
Jul 28
|
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
|
|
Jul 24
|
Exploring Three High Growth Tech Stocks In Asia
|
|
Jul 24
|
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
|
|
Jul 16
|
3 Asian Growth Companies With High Insider Ownership And 58% Earnings Growth
|
|
Jul 16
|
Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.6%
|
|
Jul 16
|
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
|
|
Jul 13
|
China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
|
|
Jul 3
|
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
|
|
Jul 3
|
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
|
|
Jun 16
|
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
|
|
Jun 2
|
Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal
|
|
Apr 25
|
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
|
|
Apr 25
|
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
|
|
Apr 25
|
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
|
|
Apr 25
|
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
|
|
Apr 24
|
Akeso and Summit notch another Phase III win with their Keytruda competitor
|
|
Apr 23
|
Why Is Summit Therapeutics Stock Soaring On Wednesday?
|
|
Apr 23
|
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
|
|
Feb 14
|
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
|